0001127602-23-018065.txt : 20230606 0001127602-23-018065.hdr.sgml : 20230606 20230606165930 ACCESSION NUMBER: 0001127602-23-018065 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230605 FILED AS OF DATE: 20230606 DATE AS OF CHANGE: 20230606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Timothy Eugene CENTRAL INDEX KEY: 0001707000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 23996792 MAIL ADDRESS: STREET 1: 800 BOYLSTON ST., SUITE 3310 STREET 2: PRUDENTIAL TOWER C/O AJU IB INVESTMENT CITY: BOSTON STATE: MA ZIP: 02199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0407 4 2023-06-05 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001707000 Sullivan Timothy Eugene C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Financial Officer 1 Common Stock 56232 I The Timothy E Sullivan Irrevocable Trust of 2023 Common Stock 2023-06-05 4 M 0 69779 10.03 A 147492 D Common Stock 2023-06-05 4 S 0 1600 90.6044 D 145892 D Common Stock 2023-06-05 4 S 0 30609 87.7886 D 115283 D Common Stock 2023-06-05 4 S 0 7064 88.3649 D 108219 D Common Stock 2023-06-05 4 S 0 30506 89.8259 D 77713 D Stock Option (Right to Buy) 10.03 2023-06-05 4 M 0 69779 0 D 2027-10-18 Common Stock 69779 288840 D The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein. This is a scheduled exercise & sale from 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $90.380 - $90.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.155 - $88.150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $88.160 - $89.130. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $89.375 - $90.370. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This option was granted on October 18, 2017 and fully vested. /s/s David Watson, attorney-in-fact for Timothy Sullivan 2023-06-06